- Home
- WPC vs INCY Comparison
WPC vs INCY Comparison
Compare WPC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPC
- INCY
- Stock Information
- Founded
- WPC 1973
- INCY 1991
- Country
- WPC United States
- INCY United States
- Employees
- WPC N/A
- INCY N/A
- Industry
- WPC Real Estate Investment Trusts
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WPC Real Estate
- INCY Health Care
- Exchange
- WPC Nasdaq
- INCY Nasdaq
- Market Cap
- WPC 14.7B
- INCY 17.0B
- IPO Year
- WPC 1998
- INCY 1993
- Fundamental
- Price
- WPC $67.63
- INCY $105.55
- Analyst Decision
- WPC Hold
- INCY Buy
- Analyst Count
- WPC 9
- INCY 19
- Target Price
- WPC $112.38
- INCY $89.19
- AVG Volume (30 Days)
- WPC 1.3M
- INCY 2.8M
- Earning Date
- WPC 10-28-2025
- INCY 10-28-2025
- Dividend Yield
- WPC 5.38%
- INCY N/A
- EPS Growth
- WPC N/A
- INCY 3878.02
- EPS
- WPC 1.65
- INCY 5.90
- Revenue
- WPC $1,670,291,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- WPC $7.52
- INCY $19.33
- Revenue Next Year
- WPC $3.54
- INCY $10.47
- P/E Ratio
- WPC $40.98
- INCY $17.64
- Revenue Growth
- WPC 5.29
- INCY 18.09
- 52 Week Low
- WPC $52.91
- INCY $53.56
- 52 Week High
- WPC $69.79
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- WPC 54.81
- INCY 68.24
- Support Level
- WPC $64.72
- INCY $91.16
- Resistance Level
- WPC $68.16
- INCY $109.28
- Average True Range (ATR)
- WPC 1.13
- INCY 4.59
- MACD
- WPC 0.16
- INCY 0.49
- Stochastic Oscillator
- WPC 77.86
- INCY 80.28
About WPC W. P. Carey Inc. REIT
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. majority of the company's revenue comes from properties in the USA. Its Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.